Top

Published in:

01-02-2017 | ORIGINAL ARTICLE

Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis

Authors: Damien Bergeat, Michel Rayar, Yann Mouchel, Aude Merdrignac, Bernard Meunier, Astrid Lièvre, Karim Boudjema, Laurent Sulpice

Published in: Langenbeck's Archives of Surgery | Issue 1/2017

Abstract

Purpose

Bevacizumab associated with conventional chemotherapy has become standard care in the management of metastatic colorectal cancer. However, its impact on outcomes after liver resections (LRs) remains debated. The aim of this study was to evaluate the impact of neoadjuvant bevacizumab-based chemotherapy (BBC) on postoperative outcomes of LR for colorectal liver metastasis (CLM) using a validated approach.

Methods

All patients who received neoadjuvant therapy for CLMs between January 2005 and May 2011 were included. Risk factors for major complications (Clavien ≥3) were analyzed by univariate and multivariate analysis. Evaluation of BBC’s impact on morbidity was conducted after a propensity score adjustment on factors identified to influence major complications (MCs).

Results

LR for CLMs after neoadjuvant chemotherapy was performed in 199 patients (127 men and 72 women). Major LR was performed on 111 patients (55.78%), and MCs occurred in 41 cases (20.6%). After multivariate analyses, major LR (OR 2.85; 95% CI 1.29–6.85; P = 0.013) and combined resections of both the primary tumor and CLMs (OR 7.12; 95% CI: 2.6–20.5; P < 0.001) were independent predictive factors for MCs. After a propensity score matching, 56 patients with a BBC regimen were compared to 112 patients without BBC. No difference in terms of biliary fistula occurrence (P = 0.94) or 90-day mortality (P = 0.66) was found. Both in the univariate and multivariate analyses, BBC was not associated with MCs (P = 0.95).

Conclusion

The present study using propensity score matching demonstrated that BBC did not impair outcomes of LR for CLM.

Available only for authorised users

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer Oxf Engl 1990 49:1374–1403. doi:10.1016/j.ejca.2012.12.027

Gunderson LL, Jessup JM, Sargent DJ et al (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol Off J Am Soc Clin Oncol 28:264–271. doi:10.1200/JCO.2009.24.0952 CrossRef

Ye L-C, Liu T-S, Ren L et al (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol Off J Am Soc Clin Oncol 31:1931–1938. doi:10.1200/JCO.2012.44.8308 CrossRef

Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075. doi:10.1016/S1470-2045(14)70330-4 CrossRefPubMed

Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683. doi:10.1200/JCO.2008.20.5278 CrossRefPubMedPubMedCentral

Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol 15:938–946

Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg 240:644–658. doi:10.1097/01.sla.0000141198.92114.f6 CrossRefPubMedPubMedCentral

Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol Off J Am Soc Clin Oncol 26:1635–1641. doi:10.1200/JCO.2007.13.7471 CrossRef

Brouquet A, Abdalla EK, Kopetz S et al (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol Off J Am Soc Clin Oncol 29:1083–1090. doi:10.1200/JCO.2010.32.6132 CrossRef

10.

Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215. doi:10.1016/S1470-2045(13)70447-9 CrossRefPubMed

11.

Van Cutsem E, Lenz H-J, Köhne C-H et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:692–700. doi:10.1200/JCO.2014.59.4812 CrossRef

12.

Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol Off J Eur Soc Med Oncol ESMO 23:2479–2516. doi:10.1093/annonc/mds236 CrossRef

13.

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016. doi:10.1016/S0140-6736(08)60455-9 CrossRefPubMedPubMedCentral

14.

Wicherts DA, Miller R, de Haas RJ et al (2008) Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248:994–1005. doi:10.1097/SLA.0b013e3181907fd9 CrossRefPubMed

15.

Tanaka K, Takakura H, Takeda K et al (2009) Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 250:935–942CrossRefPubMed

16.

Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol 23:3697–3705. doi:10.1200/JCO.2005.05.112 CrossRef

17.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 CrossRefPubMed

18.

Okines A, Puerto OD, Cunningham D et al (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer first BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033–1038. doi:10.1038/sj.bjc.6605259 CrossRefPubMedPubMedCentral

19.

Masi G, Loupakis F, Salvatore L et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11:845–852. doi:10.1016/S1470-2045(10)70175-3 CrossRefPubMed

20.

Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180. doi:10.1002/jso.20301 CrossRefPubMed

21.

Tamandl D, Gruenberger B, Klinger M et al (2010) Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 252:124–130. doi:10.1097/SLA.0b013e3181deb67f CrossRefPubMed

22.

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. doi:10.1097/01.sla.0000133083.54934.ae CrossRefPubMedPubMedCentral

23.

Koch M, Garden OJ, Padbury R et al (2011) Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 149:680–688. doi:10.1016/j.surg.2010.12.002 CrossRefPubMed

24.

Balzan S, Belghiti J, Farges O et al (2005) The ???50-50 criteria??? On postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242:824–829. doi:10.1097/01.sla.0000189131.90876.9e CrossRefPubMedPubMedCentral

25.

Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47. doi:10.1016/S1470-2045(09)70330-4 CrossRefPubMed

26.

Wong R, Cunningham D, Barbachano Y et al (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol Off J Eur Soc Med Oncol ESMO 22:2042–2048. doi:10.1093/annonc/mdq714 CrossRef

27.

Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:1830–1835. doi:10.1200/JCO.2007.13.7679 CrossRef

28.

Cutsem EV, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842–1847. doi:10.1093/annonc/mdp233 CrossRefPubMed

29.

Gruenberger T, Bridgewater J, Chau I et al (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26:702–708. doi:10.1093/annonc/mdu580 CrossRefPubMed

30.

Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106. doi:10.1016/j.jamcollsurg.2007.06.290 CrossRefPubMed

31.

D’Angelica M, Kornprat P, Gonen M et al (2006) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759–765. doi:10.1245/s10434-006-9074-0 CrossRefPubMed

32.

Rubbia-Brandt L, Lauwers GY, Wang H et al (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439. doi:10.1111/j.1365-2559.2010.03511.x CrossRefPubMed

33.

Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254–5260. doi:10.1200/JCO.2008.17.7857 CrossRefPubMed

34.

Li D-B, Ye F, Wu X-R et al (2013) Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol WJG 19:761–768. doi:10.3748/wjg.v19.i5.761 CrossRefPubMed

35.

Viganò L, Capussotti L, De Rosa G et al (2013) Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 258:731–740 . discussion 741–742 doi:10.1097/SLA.0b013e3182a6183e CrossRefPubMed

36.

Robinson SM, Wilson CH, Burt AD et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:4287–4299. doi:10.1245/s10434-012-2438-8 CrossRefPubMedPubMedCentral

37.

Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 15:460–466CrossRef

38.

Kishi Y, Zorzi D, Contreras CM et al (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17:2870–2876. doi:10.1245/s10434-010-1166-1 CrossRefPubMed

39.

Mahfud M, Breitenstein S, El-Badry AM et al (2010) Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 34:92–100. doi:10.1007/s00268-009-0251-8 CrossRefPubMed

40.

Deleve LD, Wang X, Tsai J et al (2003) Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 125:882–890CrossRefPubMed

41.

Wang H, Keiser JA (1998) Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 83:832–840CrossRefPubMed

42.

Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7. doi:10.1097/01.sla.0000193603.26265.c3 CrossRefPubMedPubMedCentral

43.

Mayo SC, Pulitano C, Marques H et al (2013) Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg 216:707–718. doi:10.1016/j.jamcollsurg.2012.12.029 CrossRefPubMedPubMedCentral

44.

Mokart D, Giaoui E, Barbier L et al (2016) Postoperative sepsis in cancer patients undergoing major elective digestive surgery is associated with increased long-term mortality. J Crit Care 31:48–53. doi:10.1016/j.jcrc.2015.10.001 CrossRefPubMed

45.

Krarup P-M, Nordholm-Carstensen A, Jorgensen LN, Harling H (2014) Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a Nationwide cohort study. Ann Surg 259:930–938. doi:10.1097/SLA.0b013e3182a6f2fc CrossRefPubMed

46.

Nagai S, Fujii T, Kodera Y et al (2011) Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Ann Surg Oncol 18:2329–2337. doi:10.1245/s10434-011-1604-8 CrossRefPubMed

47.

van der Gaag NA, Harmsen K, Eshuis WJ et al (2014) Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 40:551–558. doi:10.1016/j.ejso.2013.12.012

48.

Markar S, Gronnier C, Duhamel A et al (2015) The impact of severe anastomotic leak on long-term survival and cancer recurrence after surgical resection for esophageal malignancy. Ann Surg 262:972–980. doi:10.1097/SLA.0000000000001011 CrossRefPubMed

49.

Blazer DG, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol 26:5344–5351. doi:10.1200/JCO.2008.17.5299 CrossRef

50.

Chun Y, Vauthey J, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344. doi:10.1001/jama.2009.1755 CrossRefPubMedPubMedCentral

Title: Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis
Authors: Damien Bergeat
Michel Rayar
Yann Mouchel
Aude Merdrignac
Bernard Meunier
Astrid Lièvre
Karim Boudjema
Laurent Sulpice
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 1/2017
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-017-1551-3

At a glance: The STEP trials

Springer Medicine

Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Long-term outcome after laparoscopic gastrectomy: a multicenter retrospective study

Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors

3D vs. 2D imaging in laparoscopic surgery—an advantage? Results of standardised black box training in laparoscopic surgery

Stage-directed therapy of pleural empyema

Liver mobilization and liver hanging for totally laparoscopic right hepatectomy: an easy way to do it

Preserving infrapyloric vein reduces postoperative gastric stasis after laparoscopic pylorus-preserving gastrectomy